TXG — 10x Genomics, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1770787 ·
Last close
$85.71
Market Cap
$10.30B
52W High
$86.16
52W Low
$11.16
ADV30
2,873,277
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 150,843,000 | 106,178,000 | -17,046,000 | -13,470,000 | 1,015,759,000 | 490,285,000 | 201,435,000 |
| Dec 2025 | 166,030,000 | 113,045,000 | -19,541,000 | -16,252,000 | 1,041,365,000 | 473,966,000 | 245,039,000 |
| Sep 2025 | 149,002,000 | 100,307,000 | -32,242,000 | -27,472,000 | 1,027,361,000 | 432,508,000 | 242,241,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$127,819,000
Investing CF
$-12,856,000
Financing CF
$-2,036,000
CapEx
$-5,639,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.59
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,524,061,000
Inventory
$53,487,000
Receivables
$56,137,000
ST Investments
$49,563,000
EBIT TTM
$39,149,000
Pretax Income TTM
$-19,248,000
Interest Exp TTM
$3,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$616,910,976
EBITDA
$-41,201,000
Free Cash Flow
$179,656,000
Enterprise Value
$8,463,434,240
Total Cash
$552,033,024
Total Debt
$78,796,000
Shares Out
120,212,296
Trailing EPS
$-0.60
Book Value
$6.31
ROE
-9.4%
ROA
-5.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 642,823,000 | -110,885,000 | -43,544,000 | 1,041,365,000 | 245,039,000 | 796,326,000 | 136,050,000 |
| Dec 2024 | 610,785,000 | -194,559,000 | -182,627,000 | 918,636,000 | 208,502,000 | 710,134,000 | 6,664,000 |
| Dec 2023 | 618,727,000 | -204,349,000 | -255,099,000 | 965,143,000 | 224,100,000 | 741,043,000 | -15,197,000 |
| Dec 2022 | 516,409,000 | -167,944,000 | -166,000,000 | 1,028,980,000 | 223,237,000 | 805,743,000 | -33,606,000 |
TTM Snapshot
Revenues TTM
$563,117,000
NetIncome TTM
$-189,968,000
OpCashFlow TTM
$0
Assets (Latest)
$918,636,000
Forward EPS
$0.20
Max Pain — expiry 2026-10-16
max pain strike: $70.00 · spot: $86.29 · call oi: 2,131 · put oi: 1,336
Expected Move to 2026-10-16:
±$13.10
(15.18%) —
implied range
$73.19 –
$99.39
· ATM straddle on $85.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVTR | Avantor, Inc. | $10.31B | $15.25 | — |
| SNROY | Sanrio Company, Ltd./ADR | $10.35B | $17.07 | — |
| NYT | NEW YORK TIMES CO | $10.24B | $63.83 | — |
| NWSA | NEWS CORP | $10.22B | $28.49 | — |
| RTO | RENTOKIL INITIAL PLC /FI | $10.39B | $20.64 | — |
News headlines (Yahoo Finance, 1h cache)
Q2 Rundown: 10x Genomics (NASDAQ:TXG) Vs Other Life Sciences Tools & Services Stocks
2026-09-22 13:33 · Yahoo
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
2026-09-22 11:10 · Yahoo
10x Genomics (TXG) Stock May Look Pricey As Oncology AI News Lands
2026-09-19 13:10 · Yahoo
Transcriptome Sequencing Market - Global Forecast to 2035; Bulk RNA-Seq Maintains Its Technology Market Lead
2026-09-10 11:03 · Yahoo
Multiomics Market Report Now Available — See Why Spatial Omics Is Set to Outgrow Single-Cell as the Field's Next Growth Driver
2026-09-08 15:51 · Yahoo
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
2026-09-03 17:51 · Yahoo
10x Genomics Needs "Meaningful' Growth in Single-Cell Business, RBC Says
2026-09-01 15:22 · Yahoo
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
2026-08-31 17:12 · Yahoo
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
2026-08-28 18:38 · Yahoo
3 Small-Cap Stocks with Open Questions
2026-08-25 10:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.